These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 18050585)

  • 1. Pharmacologic management of type 2 diabetes: a review for dentistry.
    Little JW; Rhodus NL
    Gen Dent; 2007; 55(6):564-71; quiz 572-3, 599-600. PubMed ID: 18050585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the pharmacotherapeutic options for treating type 2 diabetes.
    Kruger DF
    Diabetes Educ; 2008; 34 Suppl 3():60S-65S. PubMed ID: 18525066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consulting on the patient with type 2 diabetes: matching medication to disease mechanism.
    Manag Care; 2007 Jun; 16(6 Suppl 5):2-11. PubMed ID: 17703795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating insulin in patients with type 2 diabetes.
    Aoki TJ; White RD
    J Fam Pract; 2007 Aug; 56(8 Suppl Hot Topics):S12-20. PubMed ID: 18667139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The stepwise approach to the management of type 2 diabetes.
    Warren RE
    Diabetes Res Clin Pract; 2004 Sep; 65 Suppl 1():S3-8. PubMed ID: 15315864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
    Nathanson D; Nyström T
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood obesity and type 2 diabetes mellitus.
    Hannon TS; Rao G; Arslanian SA
    Pediatrics; 2005 Aug; 116(2):473-80. PubMed ID: 16061606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm.
    Green J; Feinglos M
    Int J Clin Pract Suppl; 2007 Aug; (154):3-11. PubMed ID: 17593272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blood pressure and type 2 diabetes mellitus: impact of the insulin therapy].
    Dakhli S; Lamine S; Lamine F; Trabelsi N; Aouididi F; Zouaoui C; Mami FB; Achour A
    Tunis Med; 2007 Nov; 85(11):945-50. PubMed ID: 19166146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic interventions for type 1 and type 2 diabetes.
    Fain JA; Miller DK
    Nurs Clin North Am; 2006 Dec; 41(4):589-604, vii. PubMed ID: 17059976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among children and adolescents.
    Liberman JN; Berger JE; Lewis M
    Arch Pediatr Adolesc Med; 2009 Apr; 163(4):357-64. PubMed ID: 19349565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX
    Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of oral hypoglycemic drugs in the metabolic control of patients with gestational diabetes].
    Valdés R E; Soto-Chacón E; Lahsen M R; Barrera H C; Candía P P
    Rev Med Chil; 2008 Jul; 136(7):915-20. PubMed ID: 18949170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.
    Uwaifo GI; Ratner RE
    Am J Cardiol; 2007 Feb; 99(4A):51B-67B. PubMed ID: 17307058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.
    Carpino PA; Goodwin B
    Expert Opin Ther Pat; 2010 Dec; 20(12):1627-51. PubMed ID: 21083519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to insulin in type-2 diabetes: high hurdles or Santiago way?
    Rotella CM; Pala L
    Acta Diabetol; 2008 Jun; 45(2):67-74. PubMed ID: 18408882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?
    Giugliano D; Standl E; Vilsbøll T; Betteridge J; Bonadonna R; Campbell IW; Schernthaner GH; Staels B; Trichopoulou A; Farinaro E
    Acta Diabetol; 2009 Sep; 46(3):173-81. PubMed ID: 19543848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.